These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 23111360)

  • 1. Prognostic value of positron emission tomography/computed tomography findings in limited-stage small cell lung cancer before chemoradiation therapy.
    Gomez DR; Gladish GW; Wei X; Kotamarti KR; Allen PK; Cox JD; O'Reilly MS; Erasmus JJ; Fossella FV; Komaki R
    Am J Clin Oncol; 2014 Feb; 37(1):77-80. PubMed ID: 23111360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Value of Preradiotherapy (18)F-FDG PET/CT Volumetrics in Limited-Stage Small-Cell Lung Cancer.
    Ong LT; Dunphy M; Foster A; Woo KM; Zhang Z; Perez CA; Pietanza CM; Rosenzweig KE; Gelblum DY; Rimner A; Wu AJ
    Clin Lung Cancer; 2016 May; 17(3):184-8. PubMed ID: 26320828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial.
    Machtay M; Duan F; Siegel BA; Snyder BS; Gorelick JJ; Reddin JS; Munden R; Johnson DW; Wilf LH; DeNittis A; Sherwin N; Cho KH; Kim SK; Videtic G; Neumann DR; Komaki R; Macapinlac H; Bradley JD; Alavi A
    J Clin Oncol; 2013 Oct; 31(30):3823-30. PubMed ID: 24043740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of PET staging in limited-stage small-cell lung cancer.
    Xanthopoulos EP; Corradetti MN; Mitra N; Fernandes AT; Kim M; Grover S; Christodouleas JP; Evans TL; Stevenson JP; Langer CJ; Lee TT; Pryma DA; Lin LL; Simone CB; Apisarnthanarax S; Rengan R
    J Thorac Oncol; 2013 Jul; 8(7):899-905. PubMed ID: 23608814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of 18F-fluorodeoxyglucose uptake by positron emission tomography for non-small cell lung cancer patients treated with radical radiotherapy.
    Ikushima H; Dong L; Erasmus J; Allen P; McAleer MF; Zhuang Y; Sasaki R; Komaki R
    J Radiat Res; 2010; 51(4):465-71. PubMed ID: 20508373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Value of Metabolic Parameters of Metastatic Lymph Nodes on
    Jin F; Qu B; Fu Z; Zhang Y; Han A; Kong L; Yu J
    Clin Lung Cancer; 2018 Jan; 19(1):e101-e108. PubMed ID: 28690012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective Study of Serial Imaging Comparing Fluorodeoxyglucose Positron Emission Tomography (PET) and Fluorothymidine PET During Radical Chemoradiation for Non-Small Cell Lung Cancer: Reduction of Detectable Proliferation Associated With Worse Survival.
    Everitt S; Ball D; Hicks RJ; Callahan J; Plumridge N; Trinh J; Herschtal A; Kron T; Mac Manus M
    Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):947-955. PubMed ID: 29063854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Value of Pretherapeutic Tumor-to-Blood Standardized Uptake Ratio in Patients with Esophageal Carcinoma.
    Bütof R; Hofheinz F; Zöphel K; Stadelmann T; Schmollack J; Jentsch C; Löck S; Kotzerke J; Baumann M; van den Hoff J
    J Nucl Med; 2015 Aug; 56(8):1150-6. PubMed ID: 26089549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of metabolic parameters measured by (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with small cell lung cancer.
    Zhu D; Ma T; Niu Z; Zheng J; Han A; Zhao S; Yu J
    Lung Cancer; 2011 Sep; 73(3):332-7. PubMed ID: 21292341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of 18 F-fluorodeoxyglucose - positron emission tomography after treatment in patients with limited stage small cell lung cancer.
    Onitilo AA; Engel JM; Demos JM; Mukesh B
    Clin Med Res; 2008 Sep; 6(2):72-7. PubMed ID: 18801952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of metabolic tumor volume on repeated 18F-FDG PET/CT for early prediction of survival in locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
    Huang W; Fan M; Liu B; Fu Z; Zhou T; Zhang Z; Gong H; Li B
    J Nucl Med; 2014 Oct; 55(10):1584-90. PubMed ID: 25214640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Revisiting the prognostic value of preoperative (18)F-fluoro-2-deoxyglucose ( (18)F-FDG) positron emission tomography (PET) in early-stage (I & II) non-small cell lung cancers (NSCLC).
    Agarwal M; Brahmanday G; Bajaj SK; Ravikrishnan KP; Wong CY
    Eur J Nucl Med Mol Imaging; 2010 Apr; 37(4):691-8. PubMed ID: 19915840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretreatment FDG-PET metrics in stage III non-small cell lung cancer: ACRIN 6668/RTOG 0235.
    Ohri N; Duan F; Machtay M; Gorelick JJ; Snyder BS; Alavi A; Siegel BA; Johnson DW; Bradley JD; DeNittis A; Werner-Wasik M
    J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25688115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Confirmation of the prognostic value of pretherapeutic tumor SUR and MTV in patients with esophageal squamous cell carcinoma.
    Hofheinz F; Li Y; Steffen IG; Lin Q; Lili C; Hua W; van den Hoff J; Zschaeck S
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1485-1494. PubMed ID: 30949816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Follow-up or Surveillance (18)F-FDG PET/CT and Survival Outcome in Lung Cancer Patients.
    Antoniou AJ; Marcus C; Tahari AK; Wahl RL; Subramaniam RM
    J Nucl Med; 2014 Jul; 55(7):1062-8. PubMed ID: 24777290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of maximum standardized uptake value measured by pretreatment 18F-FDG PET/CT in locally advanced head and neck squamous cell carcinoma.
    Cacicedo J; Fernandez I; Del Hoyo O; Navarro A; Gomez-Iturriaga A; Pijoan JI; Martinez-Indart L; Escudero J; Gomez-Suarez J; de Zarate RO; Perez JF; Bilbao P; Rades D
    Clin Transl Oncol; 2017 Nov; 19(11):1337-1349. PubMed ID: 28540535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic activity on [18f]-fluorodeoxyglucose-positron emission tomography/computed tomography and glucose transporter-1 expression might predict clinical outcomes in patients with limited disease small-cell lung cancer who receive concurrent chemoradiation.
    Lee J; Kim JO; Jung CK; Kim YS; Yoo IeR; Choi WH; Jeon EK; Hong SH; Chun SH; Kim SJ; Kim YK; Kang JH
    Clin Lung Cancer; 2014 Mar; 15(2):e13-21. PubMed ID: 24368212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy.
    Lee VH; Chan WW; Lee EY; Choy TS; Ho PP; Leung DK; Lam KO; Kwong DL; Leung TW; Khong PL
    Am J Clin Oncol; 2016 Aug; 39(4):355-62. PubMed ID: 24710123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of PET/CT standardized uptake values on complete response to treatment before definitive chemoradiotherapy in stage III non-small cell lung cancer.
    Ercelep O; Alan O; Sahin D; Telli TA; Salva H; Tuylu TB; Babacan NA; Kaya S; Dane F; Ones T; Alkis H; Adli M; Yumuk F
    Clin Transl Oncol; 2019 Apr; 21(4):499-504. PubMed ID: 30229391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.